Relevant bibliographies by topics / 4-6 yrs / Journal articles
To see the other types of publications on this topic, follow the link: 4-6 yrs.

Journal articles on the topic '4-6 yrs'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '4-6 yrs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jhavar, Sameer G., Erin Bird, and Gregory P. Swanson. "Experience with artificial urinary sphincter implantation in men who underwent prior pelvic radiation therapy for prostate cancer." Journal of Clinical Oncology 32, no. 4_suppl (2014): 236. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.236.

Full text
Abstract:
236 Background: To assess outcomes after artificial urinary sphincter implantation in men who received prior pelvic radiation therapy. Methods: Between 1997 and 2012, 107 patients were identified from the Scott and White Hospital database who underwent artificial urinary sphincter implantation for urinary incontinence after prostate cancer treatment. Of these 17 were excluded for lack of follow-up data. Of the remaining 90 patients, 59 patients underwent prior surgery alone (group 1), 25 underwent prior surgery followed by pelvic radiation therapy (group 2); and 6 patients underwent prior radi
APA, Harvard, Vancouver, ISO, and other styles
2

Joh, Jae Won, Angel Callejas, Wendy Wong, Harvey Joel Cohen, Kari Nadeau, and Michael Jeng. "Role of Fas/FasL Pathway in Pediatric Idiopathic Neutropenia." Blood 110, no. 11 (2007): 3291. http://dx.doi.org/10.1182/blood.v110.11.3291.3291.

Full text
Abstract:
Abstract Idiopathic neutropenia in children is marked by low neutrophil counts (<1500/ul) circulating in the peripheral blood in patients whose disease spontaneously develops unrelated to drugs, cancers, specific antibodies, or known genetic deficiencies. Neutrophils, PBMCs and plasma were purified/obtained from 24 subjects (n=17 acute and n=7 chronic) with idiopathic neutropenia, aged 3 months to 11 yrs. After screening a number of cytokines (IL-2, IL-4 IL-6, IL-8, IL-10, IFN-γ, TNF-α), growth factors (GCSF), cell death factors (Fas, FasL, Granzymes/Perforin), and chemokines (CCL5, XCL1, X
APA, Harvard, Vancouver, ISO, and other styles
3

Arcese, William, Stella Santarone, Alessandra Picardi, et al. "Haploidentical, G-CSF Primed, Unmanipulated Bone Marrow Transplantation with Anti-CD25 Monoclonal Antibody As Part of the Gvhd Prophylaxis for Patients with High-Risk Acute Myeloid Leukemia." Blood 126, no. 23 (2015): 4368. http://dx.doi.org/10.1182/blood.v126.23.4368.4368.

Full text
Abstract:
Abstract Background. During the last years, hematopoietic stem cell transplant from haploidentical donor is increasing by using the unmanipulated graft. We report the results of allogeneic bone marrow transplantation (BMT) from haploidentical donor primed with G-CSF in patients (pts) with high-risk acute myeloid leukemia (AML), who received an uniform TBF (Thiotepa, Busulfan, Fludarabine) conditioning regimen including antitymocyte globulin and an identical GVHD prophylaxis combining MTX+CSA, MMF and an anti-CD25 monoclonal antibody (Basiliximab). Patients and Methods. Since August 2005 to Dec
APA, Harvard, Vancouver, ISO, and other styles
4

Holand, Øystein, Léon L’Italien, Robert B. Weladji, et al. "Shit happens – a glimpse into males’ mating tactics in a polygynous ungulate - the reindeer." Rangifer 32, no. 1 (2012): 65–72. http://dx.doi.org/10.7557/2.32.1.2378.

Full text
Abstract:
This is about the two big "guys", Spot and Mika, and their endeavour to propagate their genes during the mating season 2007. They were 6 and 5 years old weighting 172 and 141 kg before rut, respectively. Together with 23 other males (one 5 yrs, two 4 yrs, three 3 yrs, six 2 yrs and eleven 1 yr old) they roamed within a ~15 km2 fenced area competing for access to 87 females. Indeed, the competition was intense and all males present contributed to the dynamic observed. Especially Hot, the heaviest 4 yrs old male weighing 155 kg before rut, played a prominent role - in addition to Spot and Mika,
APA, Harvard, Vancouver, ISO, and other styles
5

Chong, Elise A., Charalambos Andreadis, Stephen J. Schuster, et al. "Long Term Follow-Up of 4-Hydroperoxycyclophosphamide Purged Autologous Bone Marrow Transplantation in Non-Hodgkin’s Lymphoma Patients with High Risk of Bone Marrow Involvement." Blood 104, no. 11 (2004): 5234. http://dx.doi.org/10.1182/blood.v104.11.5234.5234.

Full text
Abstract:
Abstract Introduction: High-dose chemotherapy and autologous stem cell transplant (ASCT) can result in long term survival for patients with advanced non-Hodgkin’s lymphoma (NHL) but relapse remains a common cause of treatment failure. Bone marrow (BM) involvement is common in NHL and there is controversy over whether or not reinfusion of BM stem cells contaminated by clonogenic tumor cells is a major cause of relapse following ASCT. Bone marrow purging can reduce the number of tumor cells in vitro, but the impact on relapse and disease free survival (DFS) remains unknown. Methods: Between 1990
APA, Harvard, Vancouver, ISO, and other styles
6

Place, Andrew E., Yana Pikman, Kristen Stevenson, et al. "Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia." Blood 126, no. 23 (2015): 3765. http://dx.doi.org/10.1182/blood.v126.23.3765.3765.

Full text
Abstract:
Abstract Introduction: Treatment of relapsed childhood acute lymphoblastic leukemia (ALL) remains a significant clinical challenge with a need for novel, more effective therapies. Pre-clinical studies have demonstrated that mTOR inhibitors have single agent activity in ALL and are synergistic with other chemotherapy agents typically used to treat ALL, including vincristine, corticosteroids, doxorubicin and L-asparaginase. Methods: Dana-Farber Cancer Institute Protocol 11-237 tested the combination of everolimus (given orally on days 1-32) with a standard reinduction regimen of prednisone (40 m
APA, Harvard, Vancouver, ISO, and other styles
7

Rokaya, Rabindra Kumar, Suman Lamichhane, Atul Adhikari, et al. "Prevalence of Depression and Drug Use Pattern among Elderly People in Living in Old Age Homes in Kathmandu." Journal of Drug Delivery and Therapeutics 13, no. 8 (2023): 96–99. http://dx.doi.org/10.22270/jddt.v13i8.6177.

Full text
Abstract:
Among 150 respondents, 25 [16.67%] respondents were normal. Out of theses 25respondents, 98 [65.33%] and 27 [18%] respondents had mild and severe depression respectively according to GDS. Regarding the socio-demographic information of the respondents, 7.33% were of age 60-64yrs, 10.66% were of 65-69 yrs, 31.33% were of 70-79 yrs, and 51.33 were of >80 yrs. 100 percent of the elderly people were regularly using drugs, and the average patient was regularly using more than 21 drug classes. The most common classes of drugs used by the older people living in Old Age Homes were antihypertensive a
APA, Harvard, Vancouver, ISO, and other styles
8

Grujić, K., M. Ćosić, and D. Petronić. "THE ANAESTHESIO IN A PATIENTS FOR PROSTATECTOMY IN A PERIOD FROM 1991. YRS TO 2000. YRS." Praxis medica 30, no. 1 (2002): 69–71. http://dx.doi.org/10.70949/pramed200201031g.

Full text
Abstract:
<p>Spinal anesthesia is one of type of central block anesthesia. It is an anesthesia of choice for surgical procedure open prostatectomy. According to our experience this type of anaesthesia is more safe than the other type of central block or regional anaesthesia in a high risk patient for surgical procedure prostatectomy. In a 10 years period we have given in a 242<br />patients spinal anaesthesia for prostatectomy. From the complication after giving of spinal anaesthesia according to our data<br />were: 1. post-spinal head-ake (3-5 days) - 5 patient
APA, Harvard, Vancouver, ISO, and other styles
9

Ghanem, Hady, Hagop M. Kantarjian, Richard E. Champlin, et al. "Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)." Blood 120, no. 21 (2012): 2001. http://dx.doi.org/10.1182/blood.v120.21.2001.2001.

Full text
Abstract:
Abstract Abstract 2001 Introduction: IFN and ASCT were the most commonly used treatment modalities for CML before 2001. The introduction of IMA as the preferred treatment for CML changed the treatment paradigms for this disease. CML pts are now expected to live longer and responses are prolonged in most cases. However, long-term outcomes including late relapses, durability of response, side effects, and late development of new medical conditions are largely unknown. Methods: We performed a chart review of pts with CML in CP treated at our institution who have survived at least 5 yrs of their i
APA, Harvard, Vancouver, ISO, and other styles
10

Fontana, Vincenzo, Eugene R. Ahn, Joaquin Jimenez, Pamela Dudkiewicz, Wenchy Jy, and Yeon S. Ahn. "Danazol in Combination with Busulfan Induces Long-Term Remission in Myeloproliferative Disorders (MPD)." Blood 104, no. 11 (2004): 4748. http://dx.doi.org/10.1182/blood.v104.11.4748.4748.

Full text
Abstract:
Abstract MPD is a clonal stem cell disorder encompassing essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), chronic myelogenous leukemia (CML). Chemotherapy has been a mainstay of therapy for the treatment of MPD but new agents including anegrelide, interferon, imatinib mesylate and thalidomide have been recently introduced. In most cases, continuous therapy is required to maintain remission and relapses are the rule when the treatment is discontinued. We report long-term remission of MPD with combined therapy of danazol and busulfan and an unusually long remission fol
APA, Harvard, Vancouver, ISO, and other styles
11

Sahay, A., G. Chinnaswamy, V. Bhat, et al. "P14.50 Clinicopathological spectrum of intracranial germ cell tumors: an Indian tertiary cancer center experience." Neuro-Oncology 21, Supplement_3 (2019): iii78. http://dx.doi.org/10.1093/neuonc/noz126.285.

Full text
Abstract:
Abstract BACKGROUND Incidence of intracranial germ cell tumors (ICGCT) in Western literature is low (0.3–0.6 %) as compared to East Asia (3–4 %), & their clinicopathological features are well documented. However, there are scant studies on ICGCT from India. MATERIAL AND METHODS Retrospective observational study of all ICGCT histologically diagnosed in our hospital from 2007–2018. Metastasis were excluded. Clinicopathological features were retrieved from hospital’s electronic medical records. RESULTS We diagnosed 82 primary ICGCT, forming approx. 0.54 % of all primary brain tumors, & 3.
APA, Harvard, Vancouver, ISO, and other styles
12

Badros, Ashraf Z., Olga Goloubeva, Saranya Chumsri, et al. "Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients." Blood 108, no. 11 (2006): 5024. http://dx.doi.org/10.1182/blood.v108.11.5024.5024.

Full text
Abstract:
Abstract AAs have the highest incidence of MM among all racial groups. The impact of race on disease presentation and outcome is the focus of this retrospective study. We analyzed 118 patients of 200 AA patients evaluated at our center from 1998 to 2006. The median age was 54 yrs (range: 28–75); 12 (10%) were younger than 40 yrs. Main presenting symptoms included pain (n= 60, 51%), spinal cord compression (n=9, 8%) and fatigue (n=26, 22%). Eleven patients (9%) were diagnosed following routine blood work and 8 (7%) progressed from prior MGUS. Four patients, all < 41 yrs, had plasma cell
APA, Harvard, Vancouver, ISO, and other styles
13

Simpkins, F., F. Abu Shahim, J. N. Bakkum-Gamez, et al. "Recurrence in ovarian carcinoma stage I A/B grade 1 and 2 with and without chemotherapy." Journal of Clinical Oncology 25, no. 18_suppl (2007): 5565. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5565.

Full text
Abstract:
5565 Background: The goal of this study was to determine the recurrence rates (R) of patients with grade 1 and 2 stage 1A and IB ovarian tumors treated with and without chemotherapy. Methods: We conducted a five-center retrospective study of patients with Stage 1A/B grade 1 and 2 ovarian carcinoma. All women underwent comprehensive staging including a minimum of unilateral salpingo-ophorectomy, unilateral pelvic and para-aortic lymphadenectomy, and omentectomy. Clear cell histologies were classified as grade 3 and excluded. The minimum cancer-free survivor follow-up was 3 years. Results: We id
APA, Harvard, Vancouver, ISO, and other styles
14

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al. "Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)." Blood 124, no. 21 (2014): 4695. http://dx.doi.org/10.1182/blood.v124.21.4695.4695.

Full text
Abstract:
Abstract BACKGROUND Fludarabine (F), cyclophosphamide (C) and rituximab (R) gave superior progression free (PFS) and overall survival (OS) versus (vs) FC in the CLL8 Study. The median age in CLL8 was 61 years compared to 72 years for CLL overall. There has been considerable debate regarding the tolerability and toxicity of FCR based therapy in older patients (pts) and those with comorbidities. METHODS Previously untreated fit pts with progressive CLL aged ≥65 were randomised to one of 3 therapy arms: (i) FR5: F 24mg/m2 po D1-5 + R iv D1 (375mg/m2 cycle 1, 500mg/m2 cycles 2-6), (ii) FCR3: F 24m
APA, Harvard, Vancouver, ISO, and other styles
15

Ku, G. Y., D. Kelsen, B. Minsky, V. Rusch, M. Bains, and D. H. Ilson. "Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience." Journal of Clinical Oncology 25, no. 18_suppl (2007): 4631. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4631.

Full text
Abstract:
4631 Background: Esophageal small cell carcinoma (ESC) is rare and accounts for <1% of all esophageal cancers. It is treated like pulmonary SC but the optimal approach of surgery, chemotherapy or radiotherapy is unknown. Prior series (Chest 107:179, Cancer 88:262) indicate a poor median overall survival (OS) of 7–12 months (mos), rare long-term (LT) survival and the need for surgery as part of curative therapy. Methods: We reviewed records of patients (pts) with ESC treated from 1980 to 2005. All pathology was reviewed at MSKCC. Results: 24 pts were identified, with records available for 21
APA, Harvard, Vancouver, ISO, and other styles
16

Arneson, Thomas J., Karynsa Cetin, Scott Stryker, et al. "Androgen deprivation therapy (ADT) use in Medicare beneficiaries with nonmetastatic (M0) prostate cancer (PC) in the United States." Journal of Clinical Oncology 30, no. 15_suppl (2012): e15169-e15169. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15169.

Full text
Abstract:
e15169 Background: ADT is well-established for metastatic PC but is also used in men with less advanced PC. Patterns of ADT use in the M0 PC setting have not been well-described. Methods: Medicare claims in 2005 for men aged ≥66 years (yrs) were assessed for use of gonadotropin-releasing hormone agonists or bilateral orchiectomy. The cohort was limited to men who, during the 15 months (mos) prior to their first 2005 ADT claim, had continuous Parts A + B coverage, a diagnosis code for PC, no claims for metastases (except lymph nodes), and no claims for ADT. Follow-up (f/u) was from ADT initiati
APA, Harvard, Vancouver, ISO, and other styles
17

Wellnitz, Krista R., Cory T. Parsons, Julia M. Dafoe, et al. "Impacts of Dam Age on Lifetime Productivity of Angus Replacement Beef Females." Animals 12, no. 20 (2022): 2768. http://dx.doi.org/10.3390/ani12202768.

Full text
Abstract:
Comprehensive cow-calf production data was utilized to evaluate the impact of dam age on lifetime productivity of Angus replacement beef females. Cows used in this study were commercial Angus replacement females born between 2006 and 2020, ranging in age from 1 to 14-yr of age (n = 3568). To determine the impact of dam age on lifetime productivity, cows were classified by age groups, specifically 2-, 3-, 4-, 5-, 6/7-, and 8-yrs old and older. The 8-yr and older group consisted of females that were up to 14-yr of age. Cow BW at breeding exhibited a cow age × dam age interaction (p < 0.01). C
APA, Harvard, Vancouver, ISO, and other styles
18

de Lima, Marcos, Daniel Couriel, Shubhra Ghosh, et al. "Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation." Blood 106, no. 11 (2005): 660. http://dx.doi.org/10.1182/blood.v106.11.660.660.

Full text
Abstract:
Abstract Older age (e.g. > 55–60 yrs) is a commonly cited indication for reduced-intensity conditioning regimens (RIC) in the treatment of myeloid leukemias. These diseases, however, may benefit from the highest possible dose intensity that can be safely delivered. Here we analyze our experience treating patients (pts) older than 55 yrs. with intravenous (IV) busulfan (Bu)-based preparative regimens. Methods: Fifty-six pts older than age 55 yrs. with MDS (n=13), AML (n=33), or CML/myeloproliferative disorder (n=10) were transplanted from 6/1997 to 12/2004 on two consecutive protocols. C
APA, Harvard, Vancouver, ISO, and other styles
19

Al-Rayess, Heba, O. Yaw Addo, Elise Palzer, et al. "Hydrocortisone Suspension Provides Similar Growth Outcomes as Hydrocortisone Tablets in Young Children With Congenital Adrenal Hyperplasia: A Cross Sectional Study." Journal of the Endocrine Society 5, Supplement_1 (2021): A84. http://dx.doi.org/10.1210/jendso/bvab048.169.

Full text
Abstract:
Abstract Young children with CAH require small doses (0.1–1.25mg) and incremental adjustments of hydrocortisone (HC) to control excess androgen production and avoid the negative effects of overtreatment. A recent 6 hour pharmacokinetic/pharmacodynamic study reported that alcohol-free HC suspension provides similar cortisol exposure to tablets (1), but more data is needed to assess its clinical efficacy. We performed a chart review to determine the effect of the alcohol-free HC suspension compared to tablets on height, weight, BMI, bone age z-scores and corrected height z-scores to target heigh
APA, Harvard, Vancouver, ISO, and other styles
20

Khouri, Issa F., Rima M. Saliba, Michael J. Keating, et al. "ZAP-70 Status May Not Predict Outcome after Non-Myeloablative Allogeneic Transplantation (NMT) in Patients with Chronic Lymphocytic Leukemia(CLL) Who Failed Conventional Chemotherapy." Blood 106, no. 11 (2005): 2038. http://dx.doi.org/10.1182/blood.v106.11.2038.2038.

Full text
Abstract:
Abstract In aggressive disease, the CLL cells usually express the 70-kD zeta-associated protein (ZAP-70). We used immunohistochemical techniques and routinely fixed, paraffin-embedded tissue to survey ZAP-70 expression in patients (pts) with CLL who received a NMT, as previously described (Modem Pathol17:954, 2004). All cases were reviewed independently by two authors. Cytoplasmic staining of non-neoplastic, reactive T cells served as an internal control in each case. Neoplasms (Pax-5 +) demonstrating ZAP-70 cytoplasmic staining in greater than 20% of tumor cells were considered positive. Pts
APA, Harvard, Vancouver, ISO, and other styles
21

Okuno, S. H., M. R. Mahoney, B. F. Kabat, et al. "A phase II evaluation of aerosolized GM-CSF (AGM-CSF) plus standard I-MAP/ GM-CSF/MAP/ surgery/ irradiation in the reduction of pulmonary metastases (P-METS) in soft tissue sarcoma (STS) patients (PTS)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10058. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10058.

Full text
Abstract:
10058 Background: P-METs remain illusive with standard treatments for STS. AGM-CSF demonstrated tolerability with promising efficacy in reducing P-METS. We evaluated the 2-yr P-MET free rate in chemonaiive pts with extremity STS. Methods: ECOG PS 0/1 and Gr 3/4 primary STS of the limb girdle/extremities, were required. Treatment sequence: 2 cycles of IMAP (Ifosfamide, Mitomycin, Doxorubicin, Cisplatin) plus s.q. GM-CSF (preload d -6 to -3, d1–14); MAP (d0, 28) during irradiation (d1–35) plus AGM-CSF 250 mcg bid (d1–7, 15- 22, 28–35); surgery; post-op irradiation plus AGM-CSF 250 mcg bid (d1–7,
APA, Harvard, Vancouver, ISO, and other styles
22

Chaulagain, Chakra P., Esha Kaul, Monika Pilichowska, Andreas K. Klein, Kellie Sprague, and Kenneth B. Miller. "Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies." Blood 122, no. 21 (2013): 5496. http://dx.doi.org/10.1182/blood.v122.21.5496.5496.

Full text
Abstract:
Abstract Allogeneic hematopoietic stem cell transplantation (SCT) is known to cure hematologic malignancies (HM). However, the risk of secondary malignancies (SM) is increased in long-term survivors. We report a series of 10 patients (pt) who developed SM and pre-malignant lesions post-SCT with predominance of squamous cell carcinomas (SCC) of oral cavity and esophagus. Ten pt with median age 40 yrs(range 21-60) at SCT were diagnosed with 13 SM in a median follow up (f/u) of 8 yrs(range 1.5-13). Five pt developed oral and esophageal SCC (4 tongue, 1 esophagus). Four of the 5 pt had chronic GVH
APA, Harvard, Vancouver, ISO, and other styles
23

Ngo, Quang N., Doreen M. Matsui, Ram N. Singh, Shayna Zelcer, and Alik Kornecki. "Anemia among Pediatric Critical Care Survivors: Prevalence and Resolution." Critical Care Research and Practice 2013 (2013): 1–6. http://dx.doi.org/10.1155/2013/684361.

Full text
Abstract:
To determine the incidence of anemia among pediatric critical care survivors and to determine whether it resolves within 6 months of discharge.Design. A prospective observational study. Patients with anemia upon discharge from the pediatric critical care unit (PCCU) underwent in hospital and post hospital discharge followup (4–6 months) for hemoglobin (Hb) levels.Setting. A medical-surgical PCCU in a tertiary care center.Patients. Patients aged 28 days to 18 years who were treated in the PCCU for over 24 hours.Measurements and Main Results. 94 (24%) out of 392 eligible patients were anemic at
APA, Harvard, Vancouver, ISO, and other styles
24

Desablens, Bernard, Réda Garidi, Bérengère Gruson, Iona Vaida та Marie Brevet. "Re-Evaluation of Prognostic Value of Seric LDH and β2-Microglobulin Levels among 248 CLL with a Median Follow-Up Time More Than 6 Years." Blood 108, № 11 (2006): 4441. http://dx.doi.org/10.1182/blood.v108.11.4441.4441.

Full text
Abstract:
Abstract Except in MD Anderson Center, seric β2-m is not recognized as a strong prognostic factor in CLL and seric LDH too, despite this factor is more and more important among lymphoma with a continuous prognostic value. So we studied 248 CLL aged less than 75 yrs, without elevated creatininemia or evident hemolysis. There were 201 pts with stage A, 29 B and 18 C and sex-ratio M/F was 1.48. Median survival time is 10 yrs and median “corrected” (i.e., without not CLL-related deaths including those due to a solid tumor because this complication is independent of initial prognostic factors of CL
APA, Harvard, Vancouver, ISO, and other styles
25

Clark, Joseph, Brendan D. Curti, Elizabeth J. Davis, et al. "Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e21005-e21005. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21005.

Full text
Abstract:
e21005 Background: HD IL2 treatment (Tx) produces durable complete responses (CRs) and surgical CRs. Patients (pts) achieving partial response (PR) and stable disease (SD) demonstrate improved survival compared with pts who progress. Methods: 7 HD IL2 Tx centers identified pts with survival > 5 years (yrs) after HD IL2. DFS was from end of IL2 to January 2017. Tx courses generally consisted of 2 1-week cycles of HD IL2, 600,000-720,000 U/kg IV every 8 hours. We collected data on pts Tx with HD IL2 alone, or HD IL2 plus local Tx (surgery or radiation (SRS) leading to CR) with survival > 5
APA, Harvard, Vancouver, ISO, and other styles
26

Räty, Riikka, Tuomo Honkanen, Esa Jantunen, et al. "Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group." Blood 124, no. 21 (2014): 1749. http://dx.doi.org/10.1182/blood.v124.21.1749.1749.

Full text
Abstract:
Abstract Background Rituximab (R) maintenance therapy bimonthly until progression has been shown in a recent randomized study to prolong duration of remission (with median follow-up of 37 months) and overall survival in elderly patients (pts) with MCL after R-CHOP, but not after R-FC, induction therapy (Kluin-Nelemans et al, N Engl J Med 2012; 367:520-31). We have previously reported initial results of 60 elderly pts with MCL treated with induction therapy consisting of 10 cycles of alternating standard CHOP and intermediate-dose AraC (combining fludarabine in 3 cycles) with 8 doses of R, foll
APA, Harvard, Vancouver, ISO, and other styles
27

Bugge, Anna, Bianca El-Naaman, Robert G. McMurray, et al. "Sex Differences in the Association between Level of Childhood Interleukin-6 and Insulin Resistance in Adolescence." Experimental Diabetes Research 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/859186.

Full text
Abstract:
The purpose of this study was to determine whether levels of interleukin-6 (IL-6) in childhood are related to insulin resistance in adolescence. Further, to explore how fatness and cardiorespiratory fitness (VO2peak) moderate this relationship.Methods. 292 nine-year-old children (n=292) were followed for 4 years. Anthropometrics andVO2peakwere measured. Fasting blood samples were analyzed for IL-6, insulin, and glucose. Homeostasis model assessment (HOMA-IR) was used as a measure of insulin resistance.Results. For girls but not boys, levels of IL-6 at age 9 yrs correlated with HOMA-IR at age 1
APA, Harvard, Vancouver, ISO, and other styles
28

Soliman, Pamela T., Charlotte C. Sun, Shannon Neville Westin, Lois M. Ramondetta, Diane C. Bodurka, and Andrea Bradford. "Longitudinal quality of life (QOL) and sexual functioning in women undergoing pelvic exenteration for gynecologic malignancies." Journal of Clinical Oncology 31, no. 15_suppl (2013): 5608. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5608.

Full text
Abstract:
5608 Background: Pelvic exenteration (PE) is en bloc resection of the pelvic organs including bladder, vagina, and rectum to treat central recurrence of a gynecologic malignancy. While this procedure has high morbidity, it is the only option for cure in some patients. The goal of this study was to assess QOL and sexual functioning in women who underwent PE with vaginal and/or bladder reconstruction. Methods: All patients were enrolled prior to PE. Surveys included the SF-12 (functional status), BIS (body image), SAQ (sexual functioning), SWD (satisfaction with decision), CES-D (depression), St
APA, Harvard, Vancouver, ISO, and other styles
29

Mueller, Martin, Michele Baccarani, Michael W. N. Deininger, et al. "Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial." Journal of Clinical Oncology 35, no. 15_suppl (2017): 7050. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7050.

Full text
Abstract:
7050 Background: Ponatinib is approved for pts with refractory CML or Ph+ ALL for whom no other TKI therapy is indicated, or for patients with T315I. Previously (Mueller ASCO ‘16), we reported the positive association of early landmark responses with ponatinib on survival at 3 yrs in heavily pretreated pts with CP-CML in PACE (NCT01207440). Here, we provide an update with survival outcomes at 4 yrs. Methods: The association of molecular (assessed in a central lab) and cytogenetic responses (CyR) at 3, 6 and 12 mo with 4-yr post-landmark PFS and OS was evaluated in CP-CML pts (n = 267). P value
APA, Harvard, Vancouver, ISO, and other styles
30

Thompson, Alexis A., Janet L. Kwiatkowski, John B. Porter та ін. "Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia". Blood 136, Supplement 1 (2020): 52–54. http://dx.doi.org/10.1182/blood-2020-135857.

Full text
Abstract:
Introduction Betibeglogene autotemcel (beti-cel; LentiGlobin for β-thalassemia) gene therapy is being evaluated for the treatment of transfusion-dependent β-thalassemia (TDT). Initial positive results of beti-cel in the phase 3 studies, HGB-207 (NCT02906202; non-β0/β0 genotypes) and HGB-212 (NCT03207009; β0/β0, β0/β+ IVS-I-110 and β+ IVS-I-110/β+ IVS-I-110 genotypes), showed 10/12 adult patients achieved transfusion independence. The studies expanded enrollment to include adolescents and children. We present interim results from pediatric patients <18 yrs who received beti-cel in HGB-20
APA, Harvard, Vancouver, ISO, and other styles
31

Wojenski, Daniel Jerzy, Heidi D. Finnes, Ross A. Dierkhising, Kristen Beth McCullough, and Steven R. Alberts. "Comparison of toxicity, efficacy, and dose modifications in obese and non-obese patients receiving modified FOLFOX6 (mFOLFOX) for metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 31, no. 4_suppl (2013): 572. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.572.

Full text
Abstract:
572 Background: There is limited data regarding chemotherapy dosing in obese mCRC patients. Methods: A retrospective, single institution, cohort study of mCRC patients receiving mFOLFOX6 (fluorouracil (5-FU) bolus omitted) was conducted between January 2002 and January 2011. Patients were stratified into: obese (BMI > 30) full dose, obese dose reduced (oxaliplatin (OX) and/or 5-FU), non-obese (BMI 18-29.9) full dose, and non-obese dose reduced. The primary endpoint was incidence of grade 3/4 myelosuppression within the first 12 wks of therapy. Secondary endpoints included incidence of any g
APA, Harvard, Vancouver, ISO, and other styles
32

Franklin, Anna R. K., Todd A. Alonzo, Robert B. Gerbing, et al. "Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials." Blood 116, no. 21 (2010): 183. http://dx.doi.org/10.1182/blood.v116.21.183.183.

Full text
Abstract:
Abstract Abstract 183 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy AYAs with acute lymphoblastic leukemia have superior survival when treated with intensive pediatric regimens compared to regimens used for older adults. To determine if a similar benefit occurred in AYAs with AML, we performed a retrospective analysis of 517 patients (pts) with AML ages 16 to 21 years (yrs), comparing outcomes between patients treated on COG (n=281), CALGB (n=149) and SWOG (n=87) studies from 1986 to 2008. We also performed stratified analyses, comparing younger t
APA, Harvard, Vancouver, ISO, and other styles
33

Stephens, Deborah M., Amy Stark, William G. Wierda, et al. "Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients." Blood 122, no. 21 (2013): 4128. http://dx.doi.org/10.1182/blood.v122.21.4128.4128.

Full text
Abstract:
Abstract CLL patients (pts) with del(17p13.1) (17p-) karyotype are typically refractory to therapy. There are limited data on clinical outcomes of large groups of these pts treated at a single institution. We aimed to develop a risk score to classify pts with de novo 17p- CLL at high risk of early treatment or death. We retrospectively reviewed records of 114 CLL pts with 17p- and no prior therapy seen at OSU from 2002-2012. Treatment free survival (TFS) was calculated from date of 1st visit until date of 1st treatment or death, censoring pts alive and treatment-free at last follow-up. Overall
APA, Harvard, Vancouver, ISO, and other styles
34

Aoki, Etsuko, Hagop Kantarjian, Susan O’Brien, et al. "Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP)." Blood 106, no. 11 (2005): 1103. http://dx.doi.org/10.1182/blood.v106.11.1103.1103.

Full text
Abstract:
Abstract Imatinib has remarkable activity in CML in all phases, with high rates of hematologic and cytogenetic response. However, in AP and BP responses are frequently less than complete hematologic remission (CHR), including partial hematologic remission (PHR) and return to chronic phase (second CP). The objective of this study was to investigate whether different responses to imatinib conferred a survival advantage in pts with CML in AP and BP. We evaluated 214 pts in AP and 76 pts in BP (11 lymphoid, 63 myeloid, 2 unclassified) treated with imatinib. Median age for AP pts was 49 yrs (range:
APA, Harvard, Vancouver, ISO, and other styles
35

Tremaskina, P., E. Loginova, T. Korotaeva, et al. "AB0918 EVALUATION OF X-RAY PROGRESSION AT 6 YEARS FOLLOW-UP OF TREAT-TO-TARGET STRATEGY IN EARLY PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1588.2–1589. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4861.

Full text
Abstract:
BackgroundIn Psoriatic arthritis (PsA) patients (pts) persistence inflammation in the peripheral joins leading bone erosions, joint space narrowing and new bone formation. Tight control of PsA disease improved joint and skin outcomes, but the number of pts with erosions increased [1]. Despite of clinical improvement no long-term treat to target (T2T) strategy data on radiographs progression yet [2].ObjectivesTo study X-ray progression in PsA pts treated according to T2Tstrategy at the early stage of disease at 6 years (yrs) follow-up.Methods30 (M/F–17/13) PsA pts fulfilling CASPAR criteria, me
APA, Harvard, Vancouver, ISO, and other styles
36

Karna, Prakash, Lauren Farrand, and Uzma Hasan. "485. Pediatrics Institutional COVID-19 Review." Open Forum Infectious Diseases 8, Supplement_1 (2021): S344. http://dx.doi.org/10.1093/ofid/ofab466.684.

Full text
Abstract:
Abstract Background Coronavirus disease (COVID-19) caused by SARS-COV2 represents global public health concern, with varied severity of illness in different ages and racial groups. This study aims to describe clinical presentation and outcomes in children aged 0-21 years in a community hospital setting in New Jersey. Methods This is a retrospective medical record review of pediatric patients (0-21 years) admitted to Saint Barnabas Medical Center between March 2020- December 2020 with confirmed diagnosis of COVID-19 infection. Diagnosis of COVID-19 infection is based on ICD-10 diagnosis code. D
APA, Harvard, Vancouver, ISO, and other styles
37

Ho, Thanh P., Brittany L. Siontis, Cornelius A. Thiels, Travis Edward Grotz, Scott H. Okuno, and Steven Ian Robinson. "Outcome and surveillance pattern in older GIST population." Journal of Clinical Oncology 40, no. 16_suppl (2022): e24016-e24016. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e24016.

Full text
Abstract:
e24016 Background: Recent studies of patients (pts) with gastrointestinal stromal tumor (GIST) have included an older patient population. The majority of these have focused on treatment, but little is known regarding the optimal duration of surveillance following surgery for localized disease. Methods: We conducted a retrospective study of pts age 70 years (yrs) and above (≥) at diagnosis (dx), who underwent surgery for their localized GIST. Charts were reviewed of GIST diagnosed between 1992 to 2016, to allow at least 5 yrs for surveillance, if performed. Demographics were analyzed and pts we
APA, Harvard, Vancouver, ISO, and other styles
38

Dimopoulos, Meletios A., Ivan Spicka, Hang Quach, et al. "Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial." Journal of Clinical Oncology 38, no. 15_suppl (2020): 8527. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8527.

Full text
Abstract:
8527 Background: Maintenance therapy delays disease progression in non-ASCT NDMM patients. However, in practice, currently used maintenance therapies may be limited to fixed duration due to toxicity and route of administration; additional options are needed. Methods: 706 non-ASCT NDMM patients who received 6–12 months of standard-of-care induction therapy and achieved at least a partial response (≥PR) were randomized 3:2, double-blind, to the oral proteasome inhibitor (PI) ixazomib (n = 425; 3 mg, cycles 1–4, then, if tolerated, 4 mg, cycle 5 onwards) vs placebo (n = 281) on days 1, 8, and 15
APA, Harvard, Vancouver, ISO, and other styles
39

LEGA, JEAN-CHRISTOPHE, VINCENT COTTIN, NICOLE FABIEN, FRANÇOISE THIVOLET-BÉJUI, and JEAN-FRANÇOIS CORDIER. "Interstitial Lung Disease Associated with Anti-PM/Scl or Anti-Aminoacyl-tRNA Synthetase Autoantibodies: A Similar Condition?" Journal of Rheumatology 37, no. 5 (2010): 1000–1009. http://dx.doi.org/10.3899/jrheum.090652.

Full text
Abstract:
Objective.To compare anti-PM/Scl autoantibody-associated interstitial lung disease (ILD) with anti-aminoacyl-tRNA synthetases (anti-ARS) autoantibody-associated ILD.Methods.We retrospectively studied 21 patients with ILD from a department of respiratory medicine, including 9 with anti-PM/Scl autoantibodies (6 women, median age 55 yrs, followup 5.5 yrs) and 12 with anti-ARS autoantibodies (6 women, median age 59 yrs, followup 2.3 yrs).Results.Pulmonary manifestations in patients with anti-PM/Scl autoantibody-associated ILD usually followed the extrapulmonary manifestations of the connective tis
APA, Harvard, Vancouver, ISO, and other styles
40

Hosing, Chitra, Rima M. Saliba, Grace-Julia Okoroji, et al. "High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age." Blood 108, no. 11 (2006): 3059. http://dx.doi.org/10.1182/blood.v108.11.3059.3059.

Full text
Abstract:
Abstract High-dose chemotherapy followed by AHCT is the treatment of choice for relapsed NHL. Often this therapy is not offered to patients over 65 yrs of age because of concerns regarding their ability to tolerate “aggressive therapy”. We present a retrospective analysis of 99 consecutive pts. who underwent AHCT for NHL at our institution from 6/96–3/06. RESULTS: Median age at AHCT was 68 yrs (range, 65–83). Seventy percent were males. Most common histologies were DLCL (55%), MCL (15%), and FL grades 1–3 (15%). Median number of chemoregimens administered prior to AHCT were 2 (range, 1–6). Med
APA, Harvard, Vancouver, ISO, and other styles
41

Bottaro, Martim, Lee E. Brown, Rodrigo Celes, Saulo Martorelli, Rodrigo Carregaro, and José Carlos de Brito Vidal. "Effect of Rest Interval on Neuromuscular and Metabolic Responses Between Children and Adolescents." Pediatric Exercise Science 23, no. 3 (2011): 311–21. http://dx.doi.org/10.1123/pes.23.3.311.

Full text
Abstract:
The purpose of this study was to compare the effect of different rest intervals and contraction velocities on muscle recovery following resistance exercise. 18 children (11.1 ± 0.52 yrs) and 19 adolescents (15.8 ± 0.49 yrs) performed three sets of 10 isokinetic repetitions at 60°/s and 180°/s. The work-to-rest ratio (W/R) was 1:2 and 1:4 for 60°/s, and 1:6 and 1:12 for 180°/s. ANOVA revealed that children demonstrated no significant decline in PT from the first to third set with any rest interval, but there was a significant (p < .05) decline for adolescents when a W/R of 1:2, 1:4 and 1:6 w
APA, Harvard, Vancouver, ISO, and other styles
42

Jacobsen, Ditte, Grethe Risum Krog, and Frederik Banch Clausen. "Early and Accurate Sex Determination by qPCR of Y Chromosome Repetitive Sequence (YRS) In Cell-Free Fetal DNA from Maternal Plasma." Journal of Applied Laboratory Medicine 3, no. 3 (2018): 346–56. http://dx.doi.org/10.1373/jalm.2018.026799.

Full text
Abstract:
Abstract Background Circulating cell-free fetal DNA (cffDNA) provides the opportunity for noninvasive prenatal diagnosis. Early knowledge of the fetal sex is essential in cases with a risk of a sex-linked genetic disease. A reliable and highly sensitive sex determination test is required for first trimester testing because of the low amounts of cffDNA. Methods First trimester blood samples from 326 pregnant women were analyzed by real-time quantitative polymerase chain reaction (qPCR) for the presence of Y chromosome repetitive sequence (YRS). Blood samples were collected from gestational week
APA, Harvard, Vancouver, ISO, and other styles
43

Al Hadidi, Samer, Obada Ehab Ababneh, Carolina D. Schinke, et al. "Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB." Journal of Clinical Oncology 41, no. 16_suppl (2023): e20053-e20053. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e20053.

Full text
Abstract:
e20053 Background: Maintenance therapy with lenalidomide in MM is associated with improved overall survival (OS). Addition of proteasome inhibitory (PI) is usually suggested for patients (pts) with high-risk disease to overcome worse outcomes. We report long-term follow up data of TT IIIB in which initial results were reported after a median follow up of 2 years (yrs) ( Nair et.al. Blood 2010). Methods: TT IIIB (NCT00572169) used, for newly diagnosed MM, 2 cycles of VTD-PACE (bortezomib, thalidomide, and dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide,
APA, Harvard, Vancouver, ISO, and other styles
44

Brubaker, Ruth B., Curt Bay, Emile Kalil, et al. "95 Growing Up with Burn Injuries - Has the Experience Changed Over Time?" Journal of Burn Care & Research 42, Supplement_1 (2021): S65—S66. http://dx.doi.org/10.1093/jbcr/irab032.099.

Full text
Abstract:
Abstract Introduction Growing up with disfigurement and functional limitations resulting from childhood burns can be challenging. Initial stages of care involve painful surgeries/dressing changes, strenuous physical & occupational therapy, pressure garments and time away from family/school activities. Few studies have examined the voiced issues faced by youth while maturing with burns. This study’s purpose was to determine if experiences in the post-injury phase differed between currently burn-injured youth vs. young adults burned as children. Methods A prior study asked Child Burn Survivo
APA, Harvard, Vancouver, ISO, and other styles
45

Telfer, Paul, Banu Kaya, Dimitris A. Tsitsikas, Filipa Barroso, and Cynthia Sangarappillai. "Hydroxyurea Therapy Does Not Impact Current Survival Estimates in the East London Sickle Cell Newborn Cohort Study." Blood 132, Supplement 1 (2018): 3655. http://dx.doi.org/10.1182/blood-2018-99-116544.

Full text
Abstract:
Abstract Background: There is a lack of data to estimate current life expectancy in adults who have had continual access to best standard of care since birth. Furthermore, the effect of disease-modifying treatments on survival has not been adequately evaluated. Data from the East London Newborn Cohort Study provide information on these outcomes in the setting of the UK National Health Service. Methods: Inclusion criteria were birth in the London boroughs of Hackney and Tower Hamlets, diagnosis by newborn screening (local programme from 1983 to 2004, and national programme from 2004 onwards), r
APA, Harvard, Vancouver, ISO, and other styles
46

Afreen, Nabi, Juhi, and Kumari Usha. "An Assessment of Labetalol and Nifedipine in the Management of Severe Pre-Eclampsia: A Comparative Study." International Journal of Current Pharmaceutical Review and Research 16, no. 3 (2024): 418–22. https://doi.org/10.5281/zenodo.12785869.

Full text
Abstract:
Aim: The aim of the present study was to compare the labetalol and Nifedipine in the management of severe preeclampsia.Methods: The study was conducted in the Department of Obstetrics and Gynaecology, Nalanda Medical Collegeand Hospital, Patna, Bihar, India for Jan 2021 to December 2021 and in this study all the cases of pregnancyinduced hypertension patients of acute hypertensive crisis admitted under OBGY department about 50 cases wasstudied. Patients of acute hypertensive crisis was divided in two groups Group A -25 patients of acute hypertensivecrisis treated with Nifedipine Group B-25 pat
APA, Harvard, Vancouver, ISO, and other styles
47

Delmonte, John, Hagop M. Kantarjian, Guillermo Garcia-Manero, et al. "Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome." Blood 110, no. 11 (2007): 441. http://dx.doi.org/10.1182/blood.v110.11.441.441.

Full text
Abstract:
Background: Tipifarnib (Zarnestra, Z) is a non-peptidomimetic farnesyltransferase inhibitor (FTI) with clinical activity in hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia. Preclinical data suggest that tipifarnib may be synergistic with some chemotherapeutic agents. Methods: We designed a phase I/II study in patients (pts) age 15–70 years, with previously untreated AML or high-risk MDS (blasts ≥ 10%), who received induction with idarubicin (Ida) 12 mg/m2/day on days 1–3, cytarabine (ara-C) 1.5 g/m2 IV over 24 hours
APA, Harvard, Vancouver, ISO, and other styles
48

Khouri, Issa F., Saliba M. Rima, Francesco Turturro, et al. "Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation." Blood 120, no. 21 (2012): 4157. http://dx.doi.org/10.1182/blood.v120.21.4157.4157.

Full text
Abstract:
Abstract Abstract 4157 Background: We previously reported promising results with nonmyeloablative (NMA) allogeneic transplantation for indolent non-Hodgkin's lymphomas (NHL) (Khouri et al, Blood 2012; 119:6373). This strategy is however less effective in aggressive, bulky, chemoresistant, or heavily pre-treated lymphomas. The BEAM-rituximab is a commonly used regimen in transplantation for NHL. Bortezomib has synergistic activity with rituximab, is effective against many NHL subtypes with moderate non-hematologic toxicity; in addition, animal models suggest that pre-transplant bortezomib may r
APA, Harvard, Vancouver, ISO, and other styles
49

Regan, Meredith M., Samuel M. Niman, Gini F. Fleming, et al. "Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT." Journal of Clinical Oncology 40, no. 16_suppl (2022): 508. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.508.

Full text
Abstract:
508 Background: Clinical trials testing adjuvant endocrine therapy (ET) have not historically limited enrollment to patients with clinically high-risk breast cancer (BC), nor estimated treatment (trt) effects prior to 5 yrs. In light of recent trial results for adjuvant CDK4/6 inhibitors, we estimated early relative and absolute trt effects of aromatase inhibitor (AI) vs tamoxifen (T), with ovarian suppression (OFS) if premenopausal, in high risk subgroups. Methods: From pts enrolled in adjuvant phase 3 randomized clinical trials BIG 1-98 (postmenopausal, 5yr AI v T), TEXT (5yr AI+OFS v T+OFS)
APA, Harvard, Vancouver, ISO, and other styles
50

Wex, P., V. Haas, and E. Utta. "Delayed results of lung volume reduction surgery in heterogeneous lung emphysema." PULMONOLOGIYA, no. 1 (February 28, 2005): 84–86. http://dx.doi.org/10.18093/0869-0189-2005-0-1-84-86.

Full text
Abstract:
The aim of the study was to search delayed results and to characterize patients with heterogeneous emphysema which do not improve their quality of life after lung volume reduction surgery. Retrospective analysis was done based on medical history reports from July, 1994, to January, 1998. The surgical lung volume reduction was performed in 81 patients (45 males and 13 females, the average age was 61.9 yrs). Postoperative mortality was 6.9 % (4 patients). Twenty-three patients died within 5 yrs after the intervention; their mean follow-up period was 33.3 months. The average follow-up period was
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography